查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600981

胰島素市場：按藥物、類型和應用分類 - 2025-2030 年全球預測

Insulin Market by Drug (Biologic, Biosimilar), Type (Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年胰島素市值為436.4億美元，預計2024年將達467.6億美元，複合年成長率為7.63%，預計到2030年將達到730.3億美元。

胰島素是糖尿病管理的重要激素，也是治療第 1 型和第 2 型糖尿病的中流砥柱。胰島素市場範圍圍繞著藥品、生物相似藥和先進的輸送系統。全球糖尿病盛行率上升、生活方式改變和肥胖率上升推動了對胰島素的需求。主要應用包括注射胰島素製劑、胰島素幫浦和新的非侵入性輸送機制。胰島素具有廣泛的最終用途，包括醫院、診所和居家照護，為不同的患者群體提供服務。

主要市場統計
基準年[2023] 436.4億美元
預測年份 [2024] 467.6億美元
預測年份 [2030] 730.3億美元
複合年成長率（%） 7.63%

市場成長的關鍵因素包括胰島素輸送系統的技術進步、政府糖尿病管理舉措的增加以及新興國家醫療保健基礎設施的加強。人們對糖尿病治療和胰島素治療益處的認知不斷提高，進一步刺激了市場擴張。吸入式胰島素和智慧胰島素筆等創新輸送方法的開發以及使用人工智慧的個人化胰島素治療存在潛在機會。公司可以利用這些趨勢，透過投資研發來開發易於使用且高效的胰島素輸送解決方案，並與醫療保健提供者合作以改善患者的治療效果。

然而，市場面臨著胰島素成本高、法規結構嚴格以及口服藥物和生活方式管理計劃等替代糖尿病治療方法的競爭等挑戰。它們也有局限性，包括潛在的副作用以及需要持續監測和劑量調整。需要開拓創新領域，包括生物相似藥產品、人工胰腺系統的進步以及考慮用於長期糖尿病管理的基因治療。

胰島素市場是一個充滿活力的市場，具有巨大的成長潛力。公司應專注於技術整合、具有成本效益的解決方案以及擴大服務不足地區獲得胰島素的機會。隨著醫療保健領域的發展，利用疾病管理的預測分析以及以患者為中心的方法可以在胰島素市場上提供顯著的競爭優勢並推動永續的業務成長。

市場動態：揭示快速發展的胰島素市場的關鍵市場洞察

供需的動態交互作用正在改變胰島素市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 隨著老年人口的增加，糖尿病和肥胖症的盛行率不斷增加
    • 胰島素輸送系統的快速發展
    • 已開發國家胰島素產品優惠報銷政策
  • 市場限制因素
    • 與胰島素藥物相關的高成本
  • 市場機會
    • 投資胰島素開發研發活動的可能性
    • 相容生物相似藥胰島素產品的核准增加
  • 市場挑戰
    • 複雜的監管環境與病患照護連續性問題

波特五力：駕馭胰島素市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解胰島素市場的外部影響

外部宏觀環境因素在塑造胰島素市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解胰島素市場的競爭狀況

對胰島素市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣胰島素市場供應商績效評估

FPNV定位矩陣是評估胰島素市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著人口老化的加劇，糖尿病和肥胖症的發生率上升
      • 胰島素輸送系統的快速發展
      • 已開發國家胰島素產品優惠報銷政策
    • 抑制因素
      • 與胰島素藥物相關的高成本
    • 機會
      • 胰島素研發活動的潛在投資
      • 相容生物相似藥胰島素產品的核准增加
    • 任務
      • 複雜的監管環境以及患者遵守治療計劃的問題
  • 市場區隔分析
    • 藥品：安全、有效、創新的生物藥品的重要用途
    • 類型：長效胰島素在較長時間內覆蓋基礎胰島素。
    • 應用：第1型糖尿病患者大量使用胰島素，需持續監測並及時給予胰島素。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按藥物分類的胰島素市場

  • 生物
  • 生物相似藥

第7章胰島素市場：依類型

  • 中效胰島素
  • 長效胰島素
  • 預混合料胰島素
  • 速效胰島素
  • 短效胰島素

第8章胰島素市場：依應用分類

  • 1型糖尿病
  • 2型糖尿病

第9章美洲胰島素市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太胰島素市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲胰島素市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 賽諾菲考慮在德國工廠投資 16 億美元以提高產量
    • Arecor 和Medtronic Diabetes 合作開發植入式幫浦中的耐熱胰島素
    • Eris Lifesciences 收購 Biocon Biologics 的印度品牌製劑業務
    • 胰島素製造商Genesis投資500-6000萬美元在海得拉巴建工廠
    • 海灣製藥工業公司「Julfar」與 Sunshine Lake Pharma 簽署突破性協議，成為中東和北非地區生物相似藥製造的先驅
    • 賽諾菲在印度推出新的長效藥物
    • 加州和製藥公司合作生產負擔得起的胰島素
    • 諾和諾德為印度患者推出每週胰島素治療
    • ADOCIA宣布與合作夥伴通化東寶合作ChaperoneLispro期試驗取得成功
    • Glenmark在印度推出第二型糖尿病及高抗藥性藥物，股價大漲
    • 禮來公司和 EVA Pharma 宣佈建立合作夥伴關係，以加強非洲永續獲得負擔得起的胰島素
    • 諾和諾德推出 Tresiba 類似物非品牌生物製藥胰島素，以擴大患者的購買選擇
    • Optum 和賽諾菲合作為未投保者提供低成本胰島素

公司名單

  • ADOCIA
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biocon Limited
  • Bioton SA
  • CardioVends
  • Eli Lilly and Company
  • Eva Pharma
  • GeneSys Biologics
  • Glenmark Pharmaceuticals Ltd.
  • Gulf Pharmaceutical Industries（Julphar）
  • MannKind Corporation
  • Merck & Co., Inc.
  • MJ Biopharm Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Wockhardt Limited
  • Zealand Pharma A/S
Product Code: MRR-03548A2B9FF7

The Insulin Market was valued at USD 43.64 billion in 2023, expected to reach USD 46.76 billion in 2024, and is projected to grow at a CAGR of 7.63%, to USD 73.03 billion by 2030.

Insulin, a crucial hormone for diabetes management, is central to both Type 1 and Type 2 diabetes treatments. The market scope for insulin revolves around pharmaceuticals, biosimilars, and advanced delivery systems. The necessity of insulin is driven by the rising global prevalence of diabetes, lifestyle changes, and increasing obesity rates. Major applications include injectable insulin formulations, insulin pumps, and emerging non-invasive delivery mechanisms. Insulin's end-use scope spans hospitals, clinics, and homecare settings, catering to diverse patient demographics.

KEY MARKET STATISTICS
Base Year [2023] USD 43.64 billion
Estimated Year [2024] USD 46.76 billion
Forecast Year [2030] USD 73.03 billion
CAGR (%) 7.63%

Key market growth influencers include technological advancements in insulin delivery systems, increased government initiatives for diabetes management, and enhanced healthcare infrastructure in emerging economies. Rising awareness about diabetes care and the advantages of insulin therapy further stimulate market expansion. Potential opportunities lie in developing innovative delivery methods, like inhalable insulin or smart insulin pens, and leveraging artificial intelligence for personalized insulin therapy. Companies can capitalize on these trends by investing in research and development to create user-friendly, efficient insulin delivery solutions and collaborate with healthcare providers to improve patient outcomes.

However, the market faces challenges such as high insulin costs, stringent regulatory frameworks, and competition from alternative diabetes treatments like oral medications and lifestyle management programs. Limitations include potential side effects and the necessity for constant monitoring and dose adjustments. Innovative areas ripe for exploration include biosimilar insulin products, advancements in artificial pancreas systems, and exploration of gene therapy for long-term diabetes management.

The insulin market presents a dynamic environment with substantial growth potential. Companies should focus on technological integration, cost-effective solutions, and expanding access to insulin in under-served regions. As the healthcare landscape evolves, aligning with patient-centric approaches and utilizing predictive analytics for disease management can offer significant competitive advantages and foster sustainable business growth in the insulin market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Insulin Market

The Insulin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of diabetes and obesity with increasing geriatric population
    • Rapid development in insulin delivery systems
    • Favorable reimbursement policies for insulin products in developed countries
  • Market Restraints
    • High cost associated with insulin drugs
  • Market Opportunities
    • Potential investments in R&D activities for insulin development
    • Rising approvals for interchangeable biosimilar insulin products
  • Market Challenges
    • Complex regulatory landscape and problems related to patient adherence to treatment regimens

Porter's Five Forces: A Strategic Tool for Navigating the Insulin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Insulin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Insulin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Insulin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Insulin Market

A detailed market share analysis in the Insulin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Insulin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Insulin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Insulin Market, highlighting leading vendors and their innovative profiles. These include ADOCIA, AstraZeneca PLC, Baxter International, Inc., Biocon Limited, Bioton S.A., CardioVends, Eli Lilly and Company, Eva Pharma, GeneSys Biologics, Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries (Julphar), MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., Wockhardt Limited, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Insulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Biologic and Biosimilar.
  • Based on Type, market is studied across Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin, Rapid-acting Insulin, and Short-acting Insulin.
  • Based on Application, market is studied across Type I Diabetes and Type II Diabetes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of diabetes and obesity with increasing geriatric population
      • 5.1.1.2. Rapid development in insulin delivery systems
      • 5.1.1.3. Favorable reimbursement policies for insulin products in developed countries
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with insulin drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Potential investments in R&D activities for insulin development
      • 5.1.3.2. Rising approvals for interchangeable biosimilar insulin products
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscape and problems related to patient adherence to treatment regimens
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features
    • 5.2.2. Type: Long-acting insulins provide basal coverage for an extended duration
    • 5.2.3. Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Insulin Market, by Drug

  • 6.1. Introduction
  • 6.2. Biologic
  • 6.3. Biosimilar

7. Insulin Market, by Type

  • 7.1. Introduction
  • 7.2. Intermediate-acting Insulin
  • 7.3. Long-acting Insulin
  • 7.4. Premixed Insulin
  • 7.5. Rapid-acting Insulin
  • 7.6. Short-acting Insulin

8. Insulin Market, by Application

  • 8.1. Introduction
  • 8.2. Type I Diabetes
  • 8.3. Type II Diabetes

9. Americas Insulin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Insulin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Insulin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Sanofi Eyes USD 1.6 Billion Investment in German Insulin Facility to Boost Production
    • 12.3.2. Arecor and Medtronic Diabetes Collaborate to Develop Thermostable Insulin for Implantable Pumps
    • 12.3.3. Eris Lifesciences Acquires India branded Formulation Business of Biocon Biologics
    • 12.3.4. Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad
    • 12.3.5. Gulf Pharmaceutical Industries 'Julphar' Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA
    • 12.3.6. Sanofi Launches New Long-Acting Insulin Drug in India
    • 12.3.7. California, Drugmaker Partner to Produce Affordable Insulin
    • 12.3.8. Novo Nordisk to Launch Once-a-Week Insulin Regime for Indian Patients
    • 12.3.9. ADOCIA Announces the Successful Phase 1 Study for BioChaperone Lispro with Partner Tonghua Dongbao
    • 12.3.10. Glenmark Launches Type 2 Diabetes and High Insulin Resistance Drug in India; Shares Jump
    • 12.3.11. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
    • 12.3.12. Novo Nordisk Launches Unbranded Biologic of Tresiba Analog Insulin to Expand Affordability Options for Patients
    • 12.3.13. Optum, Sanofi Partner on Low Cost Insulin for the Uninsured

Companies Mentioned

  • 1. ADOCIA
  • 2. AstraZeneca PLC
  • 3. Baxter International, Inc.
  • 4. Biocon Limited
  • 5. Bioton S.A.
  • 6. CardioVends
  • 7. Eli Lilly and Company
  • 8. Eva Pharma
  • 9. GeneSys Biologics
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. Gulf Pharmaceutical Industries (Julphar)
  • 12. MannKind Corporation
  • 13. Merck & Co., Inc.
  • 14. MJ Biopharm Pvt. Ltd.
  • 15. Novartis AG
  • 16. Novo Nordisk A/S
  • 17. Oramed Pharmaceuticals Inc.
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 21. Viatris Inc.
  • 22. Wockhardt Limited
  • 23. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. INSULIN MARKET RESEARCH PROCESS
  • FIGURE 2. INSULIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INSULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INSULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INSULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INSULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INSULIN MARKET DYNAMICS
  • TABLE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INSULIN MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INSULIN MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INSULIN MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INSULIN MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INSULIN MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023